Policy Statements

ASH Position It is medically inaccurate to claim sickle cell crisis as the cause of death based solely on the presence of sickled cells at autopsy. Sudden death is an extraordinarily rare occurrence in sickle cell trait and the finding of sickle cell...

The American Society of Hematology (ASH) believes that all individuals should have access to and be able to afford high-quality, clinically appropriate care, including innovative therapeutics. Hematologists treat patients with malignant hematologic d...

The American Society of Hematology (ASH) represents approximately 17,000 physicians, scientists, and medical trainees committed to the study and treatment of blood and blood-related diseases. As an organization of physicians and scientists who care f...

The American Society of Hematology (ASH) represents approximately 17,000 physicians, scientists, and medical trainees committed to the study of blood and treatment of blood-related diseases. ASH members include clinicians who specialize in treating c...

ASH Policy Statement in Support of Patient Access to Safe and Effective DrugsAs an organization of physicians and scientists who care for desperately ill patients, including those with blood cancers such as leukemia, lymphoma, and myeloma, as well as...

Background The American Society of Hematology (ASH) represents approximately 16,000 physicians, scientists, and medical trainees committed to the study and treatment of blood and blood-related diseases. ASH members include clinicians who specialize i...

Sickle cell trait is an inherited blood disorder affects approximately 8 percent of African-Americans. Unlike sickle cell disease, a serious illness in which patients have two genes that cause the production of abnormal hemoglobin, ind...

As an organization of physicians who care for desperately ill patients and scientists devoted to understanding the basic mechanisms of disease and discovering new therapies, the American Society of Hematology (ASH) is excited about the scientific pot...

Clinical research in hematology has never been more important, yet clinical hematology investigators are facing unprecedented challenges. Constantly changing and often inconsistent regulations, chaotic reimbursement policies, lack of insurance covera...

American Society of Hematology (ASH) represents over 16,000 clinicians and scientists committed to the study and treatment of blood and blood-related diseases. Hematologists were instrumental in characterizing the first stem cell identified in the bl...